2-amino-4-phenoxyphenol | 1607-51-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-amino-4-phenoxyphenol
• CAS: 1607-51-8
• 化学式: C₁₂H₁₁NO₂
• 分子量: 201.225
• InChiKey: WQYFAQXHLFJZIK-UHFFFAOYSA-N

物化性质

• 沸点：
  346.6±32.0 °C(Predicted)
• 密度：
  1.251±0.06 g/cm3(Predicted)
• 熔点：
  107-108 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-amino-4-phenoxyphenol 在 五氯化磷 作用下， 以 乙醇 、 苯 为溶剂， 反应 2.0h， 生成 2-chloro-5-phenoxybenzoxazole
  参考文献：
  名称：

  3-[1-(2-Benzoxazolyl)hydrazino]propanenitrile derivatives: inhibitors of immune complex induced inflammation

  摘要：

  3-[1-(2-Benzoxazolyl)hydrazino]propanenitrile derivatives were evaluated in the dermal and pleural reverse passive Arthus reactions in the rat. In the pleural test these compounds were effective in reducing exudate volume and accumulation of white blood cells. This pattern of activity was similar to that of hydrocortisone and different from that of indomethacin. The structural requirements for inhibiting the Arthus reactions were studied by systematic chemical modification of 1. These structure-activity relationship studies revealed that nitrogen 1' of the hydrazino group is essential for activity and must be electron rich, whereas chemical modifications of other sites of 1 had only a modest effect on activity.

  DOI：

  10.1021/jm00117a010
• 作为产物：
  描述：

  4-苯氧基苯酚 在 palladium on activated charcoal 氢气 、 硝酸 、 溶剂黄146 作用下， 以 乙酸乙酯 为溶剂， 25.0 ℃ 、303.98 kPa 条件下， 反应 1.25h， 生成 2-amino-4-phenoxyphenol
  参考文献：
  名称：

  Structure−Activity Relationship of New Growth Inhibitors of Trypanosoma cruzi

  摘要：

  Several drugs bearing the 4-phenoxyphenoxy skeleton and other closely related structures were designed, synthesized, and evaluated as antiproliferative agents against Trypanosoma cruzi, the etiologic agent of Chagas' disease. The new class of drugs was envisioned by modifying the nonpolar 4-phenoxyphenoxy moiety replacing selected aromatic protons by different groups via electrophilic aromatic substitution reactions as well as introducing a sulfur atom at the polar extreme. Of the designed compounds, sulfur-containing derivatives were shown to be potent antireplicative agents against T. cruzi. Among these drugs, 4-phenoxyphenoxyethyl thiocyanate (compound 56) proved to be an extremely active growth inhibitor of the epimastigote forms of T. cruzi and displayed an IC50 of 2.2 mu M. Under the same assay conditions, this drug was much more active than Nifurtimox, one of the drugs currently in clinical use to control this disease. This thiocyanate derivative was also a very active inhibitor against the intracellular form of the parasite at the nanomolar level. Other sulfur derivatives prepared also exhibited very potent antiproliferative action against T. cruzi. The presence of a sulfur atom at the polar extreme for this family of compounds seems to be very important for biological action because this atom was always associated with high inhibition values. 4-Phenoxyphenoxyethyl thiocyanate presents very good prospective not only as a lead drug but also as a potential chemotherapeutic agent.

  DOI：

  10.1021/jm970860z

文献信息

• Antioxidant and bisaminophenol derivative
  申请人：Shiraki Yasushi

  公开号：US20060208227A1

  公开（公告）日：2006-09-21

  The present invention provides antioxidants made of an aromatic hydroxyamine derivative having a structure represented by the general formula (I): wherein R 1 , R 2 and R 3 are each independently a hydrogen atom or an alkyl group having 1 to 20 carbon atoms; X is a hydrogen atom or an OH group; Y is a hydrogen atom or an NHR 1 group; A is a direct bond, —O—, —NH—, —SO 2 —, —CH 2 — or —C(CH 3 ) 2 —, and when an OH group and an NHR 1 group are introduced to a unilateral benzene ring, these groups are respectively bonded to adjacent positions of the benzene ring; and n is 0 or 1 with the proviso that when n is 0, R 1 is not a hydrogen atom, as well as bisaminophenol derivatives represented by the above general formula (I) wherein n is 1; R 2 and R 3 are each a hydrogen atom; X is an OH group; Y is an NHR 1 group; A is —C(CH 3 ) 2 —; and R 1 is isopropyl, isobutyl or isohexyl. The aromatic hydroxyamine derivatives having a structure represented by the general formula (I), in particular, the bisaminophenol derivatives as novel substances, exhibit an excellent oxidation-inhibiting property, and are usable as antioxidants or polymerization inhibitors.

  本发明提供一种抗氧化剂，其由一种芳香族羟胺衍生物制成，其结构由通式（I）表示： 其中，R1、R2和R3分别独立地为氢原子或具有1到20个碳原子的烷基；X为氢原子或OH基团；Y为氢原子或NHR1基团；A为直接键，-O-，-NH-，-SO2-，-CH2-或-C(CH3)2-，当OH基团和NHR1基团被引入单侧苯环时，这些基团分别与苯环的相邻位置键合；n为0或1，但当n为0时，R1不是氢原子，以及由上述通式（I）表示的双氨基酚衍生物，其中n为1；R2和R3均为氢原子；X为OH基团；Y为NHR1基团；A为-C(CH3)2-；R1为异丙基、异丁基或异己基。具有通式（I）表示的芳香族羟胺衍生物，特别是作为新物质的双氨基酚衍生物，表现出优异的抗氧化性能，并可用作抗氧化剂或聚合物抑制剂。
• ANTIOXIDANT AND BISAMINOPHENOL DERIVATIVE
  申请人：SHIRAKI Yasushi

  公开号：US20080161608A1

  公开（公告）日：2008-07-03

  The present invention provides antioxidants made of an aromatic hydroxyamine derivative having a structure represented by the general formula (I): wherein R 1 , R 2 and R 3 are each independently a hydrogen atom or an alkyl group having 1 to 20 carbon atoms; X is a hydrogen atom or an OH group; Y is a hydrogen atom or an NHR 1 group; A is a direct bond, —O—, —NH—, —SO 2 —, —CH 2 — or —C(CH 3 ) 2 —, and when an OH group and an NHR 1 group are introduced to a unilateral benzene ring, these groups are respectively bonded to adjacent positions of the benzene ring; and n is 0 or 1 with the proviso that when n is 0, R 1 is not a hydrogen atom, as well as bisaminophenol derivatives represented by the above general formula (I) wherein n is 1; R 2 and R 3 are each a hydrogen atom; X is an OH group; Y is an NHR 1 group; A is —C(CH 3 ) 2 —; and R 1 is isopropyl, isobutyl or isohexyl. The aromatic hydroxyamine derivatives having a structure represented by the general formula (I), in particular, the bisaminophenol derivatives as novel substances, exhibit an excellent oxidation-inhibiting property, and are usable as antioxidants or polymerization inhibitors.

  本发明提供了一种芳香族羟胺衍生物制备的抗氧化剂，其结构由通式（I）表示：其中，R1、R2和R3各自独立地是氢原子或具有1到20个碳原子的烷基基团；X是氢原子或羟基（OH）基团；Y是氢原子或NHR1基团；A是直接键、—O—、—NH—、—SO2—、—CH2—或—C（CH3）2—，当在一个单侧苯环上引入OH基团和NHR1基团时，这些基团分别与苯环的相邻位置结合；n为0或1，但当n为0时，R1不是氢原子。此外，本发明还提供了通式（I）所表示的双氨基酚衍生物，其中n为1；R2和R3均为氢原子；X为羟基（OH）基团；Y为NHR1基团；A为—C（CH3）2—；而R1为异丙基、异丁基或异己基。具有通式（I）所表示的芳香族羟胺衍生物，尤其是作为新化合物的双氨基酚衍生物，表现出优异的抗氧化性能，可用作抗氧化剂或聚合抑制剂。
• S1P receptor modulating compounds and use thereof
  申请人：Burli Roland

  公开号：US20080027036A1

  公开（公告）日：2008-01-31

  The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

  本发明涉及一般式（I）的化合物，其具有作为S1P受体调节剂的活性，以及使用这种化合物来治疗与不适当的S1P受体活性相关的疾病。这些化合物可以用作免疫调节剂，例如，用于治疗或预防自身免疫和相关免疫紊乱疾病，包括系统性红斑狼疮、炎症性肠病，如克隆病和溃疡性结肠炎、1型糖尿病、葡萄膜炎、牛皮癣、重症肌无力、类风湿性关节炎、非肾小球性肾病、肝炎、Behçet病、肾小球肾炎、慢性血小板减少性紫癜、溶血性贫血、肝炎和Wegner肉芽肿；以及用于治疗其他疾病。
• S1P Receptor Modulating Compounds and Use Thereof
  申请人：Burli Roland

  公开号：US20110212940A1

  公开（公告）日：2011-09-01

  The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

  本发明涉及一般式（I）的化合物，该化合物具有作为S1P受体调节剂的活性，以及使用这种化合物治疗与不适当的S1P受体活性相关的疾病。这些化合物可以用作免疫调节剂，例如，用于治疗或预防自身免疫和相关免疫性疾病，包括全身性红斑狼疮、炎症性肠病（如克罗恩病和溃疡性结肠炎）、1型糖尿病、葡萄膜炎、银屑病、重症肌无力、类风湿性关节炎、非肾小球性肾病、肝炎、Behçet病、肾小球肾炎、慢性血小板减少性紫癜、溶血性贫血、肝炎和Wegner肉芽肿；以及用于治疗其他疾病。
• Structure–activity relationship studies on 1-heteroaryl-3-phenoxypropan-2-ones acting as inhibitors of cytosolic phospholipase A₂<b>α</b>and fatty acid amide hydrolase: replacement of the activated ketone group by other serine traps
  作者：Tom Sundermann、Walburga Hanekamp、Matthias Lehr

  DOI：10.3109/14756366.2015.1057721

  日期：2016.7.3

  Cytosolic phospholipase A(2)alpha (cPLA(2)alpha) and fatty acid amide hydrolase (FAAH) are serine hydrolases. cPLA2a is involved in the generation of pro-inflammatory lipid mediators, FAAH terminates the anti-inflammatory effects of endocannabinoids. Therefore, inhibitors of these enzymes may represent new drug candidates for the treatment of inflammation. We have reported that certain 1-heteroarylpropan-2-ones are potent inhibitors of cPLA(2)alpha and FAAH. The serine reactive ketone group of these compounds, which is crucial for enzyme inhibition, is readily metabolized resulting in inactive alcohol derivatives. In order to obtain metabolically more stable inhibitors, we replaced this moiety by alpha-ketoheterocyle, cyanamide and nitrile serine traps. Investigations on activity and metabolic stability of these substances revealed that in all cases an increased metabolic stability was accompanied by a loss of inhibitory potency against cPLA2a and FAAH, respectively.